Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Currently, the treatment for ocular neovascular diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. Although it can preserve vision, repeated injections are an invasive treatment modality, leading to serious complications and reducing patient adherence to treatment. To reduce the frequency of administration, prolong the time of drug action, and avoid repeated intravitreal injections, the combination of sustained-release materials with anti-VEGF drug therapy has become an emphasis in ophthalmology. In this review, we highlight the current state of anti-VEGF technology, its challenges, and the sustained-release strategies under investigation or being used in clinical practice. Both continuous release and considerable therapeutic effects can be achieved by encapsulating anti-VEGF drugs in sustained-release materials to minimize the number of intravitreal injections. At present, two sustained-release materials are being tested in clinical research, and although basic research shows the strong therapeutic application prospects of extended-release drugs, its challenges mainly involve the discrepancy between the release rates in vitro and the efficiency of the drugs in vivo. Briefly, sustained release of anti-VEGF agents is an advantageous strategy for treating retinal angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“VEGF is a key mediator of the pathological angiogenesis and the formation of macular choroidal neovascularisation (CNV) that, without intervention, is directly responsible for vision loss in nAMD.2,4,5,7”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aflibercept is an anti-VEGF recombinant fusion protein, which was FDA approved for nAMD in 2011 and has been administered intravitreally over 20 million times worldwide to treat VEGF-mediated retinal disorders.3,7”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, repeated intravitreal injections are invasive and risk potentially blinding complications (18).”
From Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Self-citationDe Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Cheung, N., Mitchell, P., & Wong, T. Y. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62124-3 · Cited by 3,288
Polymeric systems for controlled drug release
Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., & Shakesheff, K. M. (1999) · Chemical Reviews · doi:10.1021/cr940351u · Cited by 2,633 · cited 1×
“PLGA can be processed into virtually any shape and size, can encapsulate molecules of virtually any size, and is soluble in a variety of common solvents, including chlorinated solvents, tetrahydrofuran, acetone, and ethyl acetate.(109,110) In water, PLGA is biodegraded by the hydrolysis of ester bonds.”
BackgroundIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Chitosan-based hydrogels for controlled, localized drug delivery
Bhattarai, N., Gunn, J., & Zhang, M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.07.019 · Cited by 2,451
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Jain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,717
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Mintz-Hittner, H. A., Kennedy, K. A., & Chuang, A. Z. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007374 · Cited by 1,455
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Boyer, D. S., Yoon, Y. H., Belfort, R., Bandello, F., Maturi, R. K., Augustin, A. J., Li, X.-Y., Cui, H., Hashad, Y., & Whitcup, S. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.024 · Cited by 1,122
Self-citationMechanisms of Age-Related Macular Degeneration
Ambati, J., & Fowler, B. J. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.018 · Cited by 1,021
Bhutto, I., & Lutty, G. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.04.005 · Cited by 1,005
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems
M. Ways, T., Lau, W., & Khutoryanskiy, V. (2018) · Polymers · doi:10.3390/polym10030267 · Cited by 908
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Blencowe, H., Lawn, J. E., Vazquez, T., Fielder, A., & Gilbert, C. (2013) · Pediatric Research · doi:10.1038/pr.2013.205 · Cited by 792
Oral drug absorption enhancement by chitosan and its derivatives
Thanou, M., Verhoef, J. C., & Junginger, H. E. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00231-9 · Cited by 689
Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review
McIntosh, R. L., Rogers, S. L., Lim, L., Cheung, N., Wang, J. J., Mitchell, P., Kowalski, J. W., Nguyen, H. P., & Wong, T. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.01.060 · Cited by 597
Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
Bertelmann, T., Frank, H. U., Fuchs, H. A., & Feltgen, N. (2017) · Case Reports in Ophthalmology · doi:10.1159/000475520 · Cited by 595
Retinopathy of prematurity: a review of risk factors and their clinical significance
Kim, S. J., Port, A. D., Swan, R., Campbell, J. P., Chan, R. V. P., & Chiang, M. F. (2018) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2018.04.002 · Cited by 579
The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Fleckenstein, M., Mitchell, P., Freund, K. B., Sadda, S., Holz, F. G., Brittain, C., Henry, E. C., & Ferrara, D. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.038 · Cited by 561
Campochiaro, P. A., Brown, D. M., Pearson, A., Chen, S., Boyer, D., Ruiz-Moreno, J., Garretson, B., Gupta, A., Hariprasad, S. M., Bailey, C., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.030 · Cited by 517
Chitosan hydrogels for sustained drug delivery
Peers, S., Montembault, A., & Ladavière, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.012 · Cited by 449
Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review
Rogers, S. L., McIntosh, R. L., Lim, L., Mitchell, P., Cheung, N., Kowalski, J. W., Nguyen, H. P., Wang, J. J., & Wong, T. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.01.058 · Cited by 422
Schmidt-Erfurth, U., Eldem, B., Guymer, R., Korobelnik, J.-F., Schlingemann, R. O., Axer-Siegel, R., Wiedemann, P., Simader, C., Gekkieva, M., & Weichselberger, A. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.004 · Cited by 387
VEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
Rein, D. B. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.58 · Cited by 344
Kolar, P. (2014) · Journal of Ophthalmology · doi:10.1155/2014/724780 · Cited by 329
Wu, X. S., & Wang, N. (2001) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856201744425 · Cited by 317
Sahni, J., Patel, S. S., Dugel, P. U., Khanani, A. M., Jhaveri, C. D., Wykoff, C. C., Hershberger, V. S., Pauly-Evers, M., Sadikhov, S., Szczesny, P., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.023 · Cited by 285
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Campochiaro, P. A., Marcus, D. M., Awh, C. C., Regillo, C., Adamis, A. P., Bantseev, V., Chiang, Y., Ehrlich, J. S., Erickson, S., Hanley, W. D., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.036 · Cited by 272
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3148 · Cited by 269
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00602-3 · Cited by 267
Lee, J.-H., Canny, M. D., De Erkenez, A., Krilleke, D., Ng, Y.-S., Shima, D. T., Pardi, A., & Jucker, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509069102 · Cited by 242
Nguyen, Q. D., Das, A., Do, D. V., Dugel, P. U., Gomes, A., Holz, F. G., Koh, A., Pan, C. K., Sepah, Y. J., Patel, N., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.12.031 · Cited by 236
Smart hydrogels as functional biomimetic systems
Lim, H. L., Hwang, Y., Kar, M., & Varghese, S. (2014) · Biomater. Sci. · doi:10.1039/c3bm60288e · Cited by 233
Diabetic macular edema: new concepts in patho-physiology and treatment
Zhang, X., Zeng, H., Bao, S., Wang, N., & Gillies, M. C. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-27 · Cited by 230
Hydrogels in ophthalmic applications
Kirchhof, S., Goepferich, A. M., & Brandl, F. P. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.016 · Cited by 229
Clinical pharmacology of intravitreal anti-VEGF drugs
Fogli, S., Del Re, M., Rofi, E., Posarelli, C., Figus, M., & Danesi, R. (2018) · Eye · doi:10.1038/s41433-018-0021-7 · Cited by 224
Pericyte-Endothelial Interactions in the Retinal Microvasculature
Huang, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197413 · Cited by 223
Roles of HIFs and VEGF in angiogenesis in the retina and brain
Rattner, A., Williams, J., & Nathans, J. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126655 · Cited by 219
Cooper, R. C., & Yang, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.034 · Cited by 193
VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
Arrigo, A., Aragona, E., & Bandello, F. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2064541 · Cited by 192
Holekamp, N. M., Campochiaro, P. A., Chang, M. A., Miller, D., Pieramici, D., Adamis, A. P., Brittain, C., Evans, E., Kaufman, D., Maass, K. F., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2021.09.016 · Cited by 189
ABRISHAMI, M., GANAVATI, S. Z., SOROUSH, D., ROUHBAKHSH, M., JAAFARI, M. R., & MALAEKEH-NIKOUEI, B. (2009) · Retina · doi:10.1097/iae.0b013e3181a2f42a · Cited by 184
Yasin, M. N., Svirskis, D. M., Seyfoddin, A., & Rupenthal, I. D. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.030 · Cited by 157
Review: Practical Issues in Intravitreal Drug Delivery
Maurice, D. M. (2001) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076801753162807 · Cited by 153
Fangueiro, J. F., Andreani, T., Egea, M. A., García, M. L., Souto, S. B., Silva, A. M., & Souto, E. B. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.11.025 · Cited by 152
Tseng, J., Vance, S. K., Torre, K. E. D., Mendonça, L. S., Cooney, M. J., Klancnik, J. M., Sorenson, J. A., & Freund, K. B. (2011) · Journal of Glaucoma · doi:10.1097/ijg.0b013e31820d7d19 · Cited by 136
Nicolò, M., Desideri, L. F., Vagge, A., & Traverso, C. E. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1879791 · Cited by 135
Pandit, J., Sultana, Y., & Aqil, M. (2017) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2016.1243545 · Cited by 134
Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin
Costa, J. R., Silva, N. C., Sarmento, B. F. C. C., & Pintado, M. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2344-7 · Cited by 132
Dvir, T., Banghart, M. R., Timko, B. P., Langer, R., & Kohane, D. S. (2009) · Nano Letters · doi:10.1021/nl903411s · Cited by 129
Xie, B., Jin, L., Luo, Z., Yu, J., Shi, S., Zhang, Z., Shen, M., Chen, H., Li, X., & Song, Z. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.071 · Cited by 124
Self-citationUpdates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy
Tomita, Y., Lee, D., Tsubota, K., Negishi, K., & Kurihara, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204666 · Cited by 123
Huu, V. A. N., Luo, J., Zhu, J., Zhu, J., Patel, S., Boone, A., Mahmoud, E., McFearin, C., Olejniczak, J., de Gracia Lux, C., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.001 · Cited by 122
Varshochian, R., Riazi-Esfahani, M., Jeddi‐Tehrani, M., Mahmoudi, A.-R., Aghazadeh, S., Mahbod, M., Movassat, M., Atyabi, F., Sabzevari, A., & Dinarvand, R. (2015) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35446 · Cited by 122
Yu, Y., Lau, C. M. L., Lo, A., & Chau, Y. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.2.5 · Cited by 122
Crystal Structures of Novel Vascular Endothelial Growth Factors (VEGF) from Snake Venoms
Suto, K., Yamazaki, Y., Morita, T., & Mizuno, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411395200 · Cited by 121
Branch Retinal Vein Occlusion: Natural History of Visual Outcome
Hayreh, S. S., & Zimmerman, M. B. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.5515 · Cited by 121
Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles
Wang, Y., Liu, C.-H., Ji, T., Mehta, M., Wang, W., Marino, E., Chen, J., & Kohane, D. S. (2019) · Nature Communications · doi:10.1038/s41467-019-08690-4 · Cited by 117
Mu, H., Wang, Y., Chu, Y., Jiang, Y., Hua, H., Chu, L., Wang, K., Wang, A., Liu, W., Li, Y., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474967 · Cited by 115
Retinal pigment epithelium tears: Classification, pathogenesis, predictors, and management
Ersöz, M. G., Karaçorlu, M., Arf, S., Muslubaş, I. S., & Hocaoğlu, M. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.03.004 · Cited by 102
Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions
Gillies, M. C., Arnold, J., Bhandari, S., Essex, R. W., Young, S. H., Squirrell, D., Nguyen, V., & Barthelmes, D. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.10.007 · Cited by 100
Yandrapu, S. K., Upadhyay, A. K., Petrash, J. M., & Kompella, U. B. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400487f · Cited by 99
Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes
Edington, M., Connolly, J., & Chong, V. N. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1404987 · Cited by 95
Zhang, M., Zhang, J., Yan, M., Li, H., Yang, C., & Yu, D. (2008) · PubMed Central · Cited by 93
Hussain, R. M., Shaukat, B. A., Ciulla, L. M., Berrocal, A. M., & Sridhar, J. S. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s295223 · Cited by 93
ZONE I RETINOPATHY OF PREMATURITY
Andrés Kychenthal, B., Dorta, P., & Katz, X. (2006) · Retina · doi:10.1097/01.iae.0000244285.79004.e6 · Cited by 92
Yang, J., Wang, X., Fuh, G., Yu, L., Wakshull, E., Khosraviani, M., Day, E. S., Demeule, B., Liu, J., Shire, S. J., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500160v · Cited by 89
Platania, C. B. M., Paola, L. D., Leggio, G. M., Romano, G. L., Drago, F., Salomone, S., & Bucolo, C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00248 · Cited by 88
Lois, N., Mcbain, V., Abdelkader, E., Scott, N. W., & Kumari, R. (2013) · Retina · doi:10.1097/iae.0b013e3182657fff · Cited by 88
Photocoagulation for retinal vein occlusion
Hayreh, S. S. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100964 · Cited by 88
Kertes, P. J., Galic, I. J., Greve, M. D. J., Williams, G., Rampakakis, E., Scarino, A., & Sheidow, T. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.01.013 · Cited by 86
Pham, B., Thomas, S. M., Lillie, E., Lee, T., Hamid, J. S., Richter, T. A., Janoudi, G., Agarwal, A., Sharpe, J. P., Scott, A., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022031 · Cited by 86
Zhang, X., Sun, J., Yao, J., Shan, K. Y., Liu, B.-H., Yao, M.-D., Ge, H., Jiang, Q. L., Zhao, C., & Yan, B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.092 · Cited by 80
Sangroongruangsri, S., Ratanapakorn, T., Wu, O., Anothaisintawee, T., & Chaikledkaew, U. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1507735 · Cited by 79
Rodrigues, G. A., Mason, M., Christie, L., Hansen, C., Hernandez, L. M., Burke, J. A., Luhrs, K. A., & Hohman, T. C. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25307 · Cited by 77
Khanani, A. M., Callanan, D., Dreyer, R., Chen, S., Howard, J. G., Hopkins, J. J., Lin, C.-Y., Lorenz-Candlin, M., Makadia, S., Patel, S., et al. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2020.11.004 · Cited by 76
Rapier, C. E., Shea, K. J., & Lee, A. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-93785-6 · Cited by 76
Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion
Tang, Y. P., Cheng, Y. F., Wang, S., Wang, Y., Liu, P., & Wu, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.910600 · Cited by 69
Liu, J., Zhang, X., Li, G., Xu, F., Li, S., Teng, L., Li, Y., & Sun, F. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s217038 · Cited by 65
Mortezaee, K. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117145 · Cited by 65
KSI-301: antibody biopolymer conjugate in retinal disorders
Chandrasekaran, P. R., & Madanagopalan, V. (2021) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414211027708 · Cited by 65
Research Advances in Tissue Engineering Materials for Sustained Release of Growth Factors
Zhao, H., Wu, J., Zhu, J.-J., Xiao, Z., He, C., Shi, H., Li, X., Yang, S., & Xiao, J. (2015) · BioMed Research International · doi:10.1155/2015/808202 · Cited by 62
Self-citationAdamson, P., Wilde, T. C., Dobrzynski, E., Sychterz, C. J., Polsky, R., Kurali, E., Haworth, R., Tang, C.-M., Korczynska, J., Cook, F., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.026 · Cited by 61
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
Yannuzzi, N. A., & Freund, K. B. (2019) · Clinical ophthalmology · doi:10.2147/opth.s184706 · Cited by 59
Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections
Meyer, C. H., Krohne, T. U., Charbel Issa, P., Liu, Z., & Holz, F. G. (2016) · Developments in Ophthalmology · doi:10.1159/000431143 · Cited by 57
Hoffart, L., Matonti, F., Conrath, J., Daniel, L., Ridings, B., Masson, G. S., & Chavane, F. (2010) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2010.02252.x · Cited by 52
SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT
Chhablani, J. K., Narayanan, R., Mathai, A., Yogi, R., & Stewart, M. (2015) · Retina · doi:10.1097/iae.0000000000000913 · Cited by 52
Bonnin, P., Pournaras, J.-A. C., Lazrak, Z., Cohen, S. Y., Gargasson, J. L., Gaudric, A., Levy, B. I., & Massin, P. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01526.x · Cited by 51
Brynskov, T., Munch, I. C., Larsen, T. M., Erngaard, L., & Sørensen, T. L. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14183 · Cited by 51
Liu, J., Li, S., Li, G., Li, X., Yu, C., Fu, Z., Li, X., Teng, L., Li, Y., & Sun, F. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.04.012 · Cited by 49
Self-citationHitschke, K., Bühler, R., Apell, H., & Stark, G. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01067-6 · Cited by 46
Bisht, R., Jaiswal, J. K., Chen, Y.-S., Jin, J., & Rupenthal, I. D. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1163334 · Cited by 46
Synthesis and Application of Injectable Bioorthogonal Dendrimer Hydrogels for Local Drug Delivery
Xu, L., Cooper, R. C., Wang, J., Yeudall, W. A., & Yang, H. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00166 · Cited by 46
Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact
Singh, S. R., Dogra, A., Stewart, M., Das, T., & Chhablani, J. K. (2017) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2017263 · Cited by 45
Patel, G. C., Millar, J. C., & Clark, A. F. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-26383 · Cited by 44
A Review of Aflibercept Treatment for Macular Disease
Anguita, R., Tasiopoulou, A., Shahid, S. M., Roth, J., Sim, S. Y., & Patel, P. J. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00354-1 · Cited by 42
Campbell, M., & Doyle, S. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.029 · Cited by 40
Ye, Z., Ji, Y., Ma, X., Wen, J., Wei, W., & Huang, S. (2015) · International Journal of Ophthalmology · doi:10.3980/j.issn.2222-3959.2015.04.02 · Cited by 38
Zinkernagel, M. S., Schorno, P., Ebneter, A., & Wolf, S. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.14-16204 · Cited by 37
Konstantinidis, L., Ambresin, A., Zografos, L., & Mantel, I. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01547.x · Cited by 36
Management of macular edema due to central retinal vein occlusion – The role of aflibercept
Do, D. V., Rhoades, W. R., Dickson, D., & Nguyen, Q. D. (2017) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_9_17 · Cited by 36
Gómez-Mariscal, M., Puerto, B., Muñoz-Negrete, F. J., de Juan, V., & Rebolleda, G. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04354-7 · Cited by 36
Intravitreal Medications for Retinal Vein Occlusion: Systematic Review and Meta-analysis
Lashay, A., Esfahani, H. R., Mirghorbani, M., & Yaseri, M. (2019) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v14i3.4791 · Cited by 35
Tanetsugu, Y., Tagami, T., Terukina, T., Ogawa, T., Ohta, M., & Ozeki, T. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00437 · Cited by 32
Huemer, J. C., Khalid, H., Wagner, S. K., Nicholson, L., Fu, D. J., Sim, D. A., Patel, P. J., Balaskas, K., Rajendram, R., & Keane, P. A. (2020) · Eye · doi:10.1038/s41433-020-01317-9 · Cited by 29
Yu, Y., Lin, X., Wang, Q., He, M., & Chau, Y. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10128 · Cited by 27
Huang, Y.-H., Kuo, C., Peng, I., Chang, Y.-S., Tseng, S.-H., Conway, E. M., & Wu, H. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03950-3 · Cited by 26
Neurovascular abnormalities in retinopathy of prematurity and emerging therapies
Dai, C., Xiao, J., Wang, C., Li, W., & Su, G. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02195-2 · Cited by 26
Yang, L. P. H., & McKeage, K. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0176-2 · Cited by 25
Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes
Schraermeyer, U., & Julien, S. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.748741 · Cited by 23
Fletcher, N. A., & Krebs, M. D. (2018) · RSC Advances · doi:10.1039/c7ra13014g · Cited by 20
Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments
Arrigo, A., & Bandello, F. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071102 · Cited by 19
DOUBLE RETINAL PIGMENT EPITHELIUM TEARS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Mouallem-Bézière, A., Sarraf, D., Chen, X., Capuano, V., Souied, E. H., & Querques, G. (2016) · Retina · doi:10.1097/iae.0000000000001062 · Cited by 18
Lass, J. H., Benetz, B. A., Menegay, H. J., Tsipis, C. P., Cook, J. C., Boyer, D. S., Singer, M. A., Erickson, K., Saroj, N., Vitti, R., et al. (2018) · Cornea · doi:10.1097/ico.0000000000001535 · Cited by 18
Reiter's Syndrome and Psoriasis
Maxwell, J. D., Greig, W. R., Boyle, J. A., Pasieczny, T., & Schofield, C. B. S. (1966) · Scottish Medical Journal · doi:10.1177/003693306601100103 · Cited by 17
Aflibercept Treatment Leads to Vascular Abnormalization of the Choroidal Neovascularization
Wylęgała, A., Wylęgała, F., & Wylęgała, E. (2018) · Journal of Healthcare Engineering · doi:10.1155/2018/8595278 · Cited by 17
Urban, B. E., Szwabowicz, M., & Bakunowicz‐Łazarczyk, A. (2020) · Journal of Ophthalmology · doi:10.1155/2020/4928905 · Cited by 17
Molecular Characteristics and Pathways of Avastin for the Treatment of Glioblastoma Multiforme
Spasić, M., Chow, F. E., Tu, C., Nagasawa, D. T., & Yang, I. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.05.002 · Cited by 16
KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases
Stern, H. D., & Hussain, R. M. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2052042 · Cited by 16
Burgalassi, S., Monti, D., Nicosia, N., Tampucci, S., Terreni, E., Vento, A., & Chetoni, P. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0520-x · Cited by 15
Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression
Sharma, A., Kumar, N., Parachuri, N., Kuppermann, B. D., Bandello, F. M., & Regillo, C. D. (2019) · Eye · doi:10.1038/s41433-019-0479-y · Cited by 15
Filek, R., Hooper, P. L., Sheidow, T., Gonder, J. R., Chakrabarti, S., & Hutnik, C. M. L. (2019) · Clinical ophthalmology · doi:10.2147/opth.s199758 · Cited by 13
Ashraf, M., Elkayal, H. E., & Souka, A. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13352 · Cited by 12
Effect of Long-term Anti-VEGF Treatment on Viability and Function of RPE Cells
Brinkmann, A., Winkelmann, K., Käckenmeister, T., Roider, J. B., & Klettner, A. (2021) · Current Eye Research · doi:10.1080/02713683.2021.1931344 · Cited by 12
Insuficiencia limbar secundaria a múltiples inyecciones intravítreas
Capella, M. J., de Toledo, J. Á., & de la Paz, M. F. (2011) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2010.11.018 · Cited by 11
Sen, P., Agarwal, A. A. K., Bhende, P., & Ganesan, S. (2021) · International Ophthalmology · doi:10.1007/s10792-021-02004-8 · Cited by 10
Nagai, N., Nezhad, Z. K., Daigaku, R., Saijo, S., Song, Y., Terata, K., Hoshi, A., Nishizawa, M., Nakazawa, T., Kaji, H., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118458 · Cited by 9
Kim, S. W., Woo, J. E., Yoon, Y. S., Lee, S. H., Woo, J. M., & Min, J. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190319165824 · Cited by 7
Limbal stem cell deficiency following multiple intravitreal injections
Capella, M. J., de Toledo, J. Á., & de la Paz, M. F. (2011) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/s2173-5794(11)70017-2 · Cited by 6
Sophie, R., Wang, J., & Campochiaro, P. A. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.12.043 · Cited by 4
Domańska‐Janik, K. (1972) · PubMed · Cited by 4
JIANG, G., Han, X., Kun, Q. I. A. O., & Shu, L. I. U. (2022) · Minerva Medica · doi:10.23736/s0026-4806.22.07943-5 · Cited by 4
Acar, U., Acar, D. E., Pınarlı, F. A., Demir, M. N., Beyazyıldız, E., Özdemir, Ö., Sevim, D. G., Tiryaki, M., & Sobacı, G. (2016) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12715 · Cited by 3
Research works printed but not linked: 13
- Domańska-Janik, 1972, Neuropatol Pol, 10, 17
- Kim, 2018, Surv Ophthalmol, 63, 618, 10.1016/j.survophthal · doi:10.1016/j.survophthal
- Ferrara, 2006, Retina, 26, 859, 10.1097/01.iae.0000242842 · doi:10.1097/01.iae.0000242842
- Arrigo, 2021, Pharmaceutics, 13, 10.3390/pharmaceutics.13071102 · doi:10.3390/pharmaceutics.13071102
- Zhang, 2008, Mol Vis, 14, 37
- Chandrasekaran, 2021, Ther Adv Ophthalmol, 13, 25158414211027708, 10.1177/251.58414211027708 · doi:10.1177/251.58414211027708
- Liang, 2018, Invest Ophthalmol Vis Sci, 59, 211
- 2020, Angiogenesis, Exudation and Degeneration, 8 February 2020
- Tseng, 2012, J Glaucoma, 21, 241, 10.1097/ijg.0b013e31820.d7d19 · doi:10.1097/ijg.0b013e31820.d7d19
- Mouallem, 2016, Retina, 36, 2197, 10.1097/iae.0000.000000001062 · doi:10.1097/iae.0000.000000001062
- 2019, Hawaiian Eye & Retina Annual Meeting, January 21, 2019
- Pandit, 2017, Artif Cells Nanomed Biotechnol, 45, 1397, 10.1080/21691401.20161243545 · doi:10.1080/21691401.20161243545
- Nadarassan, 2014, Invest Ophthalmol Vis Sci, 55, 1950
Cited by
Bahr, T. A., & Bakri, S. J. (2023) · Life · doi:10.3390/life13051098 · Cited by 114
Srejovic, J., Muric, M. D., Jakovljevic, V. L., Srejovic, I. M., Srećković, S., Petrovic, N. T., Todorović, D., Bolevich, S., & Šarenac-Vulović, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111850 · Cited by 89
Khanani, A. M., Boyer, D. S., Wykoff, C. C., Regillo, C. D., Busbee, B. G., Pieramici, D., Danzig, C. J., Joondeph, B. C., Major, J. C., Turpcu, A., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102394 · Cited by 76
Vascular Endothelial Growth Factor (VEGF) and Its Role in the Cardiovascular System
Florek, K., Mendyka, D., & Gomułka, K. (2024) · Biomedicines · doi:10.3390/biomedicines12051055 · Cited by 60
Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications
Kulbay, M., Wu, K. Y., Truong, D., & Tran, S. D. (2024) · Smart Molecules · doi:10.1002/smo.20230021 · Cited by 49
Metadata
- Authors
- Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X.
- Affiliations
- Tianjin Medical University Eye Hospital (CN)
- Corresponding author
- Li, Xiaorong
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-09
- Volume
- Volume 16
- Pages
- 3241-3262
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC9512290
- OpenAlex
- W4296720485
- Cited by
- 111
- References
- 145
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 23 · 2023: 10
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Natural Science Foundation of China (82171085)
- Natural Science Foundation of Tianjin City (19JCZDJC64000)
- Tianjin Research Innovation Project for Postgraduate Students (2021YJSB271)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- VEGF inhibitors, sustained drug release, retinal angiogenesis, diabetic macular edema, age-related macular degeneration, intravitreal injection, ocular neovascular disease, drug encapsulation
- MeSH terms
- Bevacizumab, Ranibizumab, Delayed-Action Preparations, Diabetic Retinopathy, Humans, Macular Edema, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.